Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $172.40. The company's market cap stands at 25.3B, with a P/E ratio of 19.61.
As of 2026-04-07, Biogen(BIIB) stock has fluctuated between $170.43 and $173.79. The current price stands at $172.40, placing the stock +1.2% above today's low and -0.8% off the high.
The Biogen(BIIB)'s current trading volume is 298.64K, compared to an average daily volume of 1.26M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $110.04.
In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $110.04.
BIIB News
Biogen (NasdaqGS:BIIB) has agreed to acquire Apellis Pharmaceuticals, adding two commercial immunology and rare disease products to its portfolio. The company...
Key Points Management aims to book a $34 million charge in the quarter. This is due to loftier anticipated spend on items such as milestone payments and resea...
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, American Water Works Co, Inc. (Symbol: AWK) has taken o...
Analyst ratings
50%
of 36 ratingsMore BIIB News
In a regulatory filing, the company stated, “Biogen (BIIB) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-pro...
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares experienced a sharp reversal as the stock’s momentum score jumped from 8.36 to 95.26 on a week-over-week basis...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Apellis Pharmaceuticals, Inc. (APLS) shares rallied 135.4% in the last trading session to close at $40.23. This move can be attributable to notable volume with...
J.P. Morgan analyst Anupam Rama has maintained their neutral stance on APLS stock, giving a Hold rating today. End of Quarter Sale - 50% Off TipRanks Unlock hed...
Technology Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars Licensing Biogen (BIIB) is bulking up its non-neurology profile wi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.